For in vitro diagnostic use. Others cobas MPX IVD cobas® MPX RMD-6800-8800-MPX-001 Multiplex HIV, HCV & HBV nucleic acid test for use on the cobas® 6800/8800 systems 06 997 708 190 6 997 708 190 06997708190 6997708190 06997708190 KIT COBAS 6800/8800 MPX 96T CE-IVD cobas MPX 00875197004618 Reagents, kits 1 kit 96 tests true 06 997 716 190 6 997 716 190 06997716190 6997716190 06997716190 KIT COBAS 6800/8800 MPX 480T CE-IVD cobas MPX 00875197004625 Reagents, kits 1 kit 480 tests true cobas® MPX, for use on cobas® 6800 and cobas® 8800 Systems, is a qualitative in vitro nucleic acid test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum. The cobas® MPX test simultaneously detects and discriminates for HIV, HCV, and HBV. The assay does not discriminate between HIV-1 Group M, HIV-1 Group O, and HIV-2.This test is intended for use to screen donor samples for HIV-1 Group M RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of Whole Blood, blood components, Source Plasma and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating or from cadaveric (non-heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of not more than six individual samples. For donors of hematopoietic stem/progenitor cells (HPCs) sourced from bone marrow, peripheral blood or cord blood, and for donors of donor lymphocytes for infusion (DLI), plasma may be tested in pools comprised of not more than six individual samples. For donations of source plasma, samples may be tested in pools comprised of not more than 96 individual samples. For all other donors, samples may only be screened as individual samples.This test is intended to be used in conjunction with licensed serology tests for HIV-1, HCV, and HBV.This test is not intended for use as an aid in diagnosis of HIV, HCV, or HBV.This test is not intended for use on samples of cord blood.cobas® MPX can be considered a supplemental test that confirms HIV infection for specimens that are repeatedly reactive on a licensed donor screening test for antibodies to HIV and reactive for HIV on the cobas® MPX test.cobas® MPX can be considered a supplemental test that confirms HCV infection for specimens that are repeatedly reactive on a licensed donor screening test for antibodies to HCV and reactive for HCV on the cobas® MPX test.cobas® MPX can be considered a supplemental test that confirms HBV infection for specimens that are repeatedly reactive on a licensed donor screening test for Hepatitis B surface antigen, and reactive for HBV on the cobas® MPX test. en The cobas® MPX test, for use on cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum.This test is intended for use to screen donor samples for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of whole blood, blood components, and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating and in testing of cadaveric (non-heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For donations of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of aliquots of individual samples. For donations from cadaveric (non-heart beating) organ and tissue donors, samples may only be screened as individual sample.For an individual sample, results are simultaneously detected and discriminated for HIV, HCV, and HBV.The cobas® MPX test can be considered a supplemental test that confirms HIV infection for samples that are repeatedly reactive on a CE-IVD test for antibodies to HIV and reactive on the cobas® MPX test.The cobas® MPX test can be considered a supplemental test that confirms HCV infection for samples that are repeatedly reactive on a CE-IVD test for antibodies to HCV and reactive on the cobas® MPX test.The cobas® MPX test can be considered a supplemental test that confirms HBV infection for samples that are repeatedly reactive on a CE-IVD test for Hepatitis B surface antigen and reactive on the cobas® MPX test.This test is not intended for use as an aid in diagnosis of infection with HIV, HCV, or HBV. en cobas® MPX, for use on cobas® 6800 and cobas® 8800 Systems is a qualitative in vitro nucleic acid screening test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum.This test is intended for use to screen do nor samples for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of whole blood, blood components, source plasma and other living donors. This test is also inte nded for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating and in testing of cadaveric (non -heart beating) donors. Plasma and serum from all donors may be screened as individual samples. For dona tions of whole blood and blood components, plasma and serum samples may be tested individually or plasma may be tested in pools comprised of not more than six individual samples. For donors of hematopoietic stem/progenitor cells (HPCs) sourced from bone marrow, peripheral blood or cord blood, and for donors of donor lymphocytes for infusion (DLI), plasma may be tested in pools comprised of not more than six individual samples. For donations of source plasma, samples may be tested in pools comprised of not more than 96 individual samples. For donations from cadaveric (non-heart beating) organ and tissue donors, samples may only be screened as individual sample.This test is intended to be used in conjunction with licensed serology tests for HIV, HCV, and HBV.For an individual sample, results are simultaneously detecte d and discriminated for HIV, HCV, and HBV.cobas® MPX can be considered a supplemental test that confirms HIV-1 infection for s amples that are repeatedly reactive on a licensed donor screening test for antibodies to HIV-1 and reactive for HIV on cobas® MPX. cobas® MPX is not intended to be used as a supplement test to confirm HIV -2 infection.cobas® MPX can be considered a supplemental test that confirms HCV infection for samples that are repeatedly reactive on a licensed donor screening test for antibodies to HCV and reactive for HCV on cobas® MPX.cobas® MPX can be considered a supplemental test that confirms HBV infection for samples that are repeatedly reactive on a licensed donor screening test for Hepatitis B surface antigen and reactive for HBV on cobas® MPX.This test is not intended for use as an aid in diagnosis of HIV, HCV, or HBV.This test is not intended for use on samples of cord blood. en The cobas® MPX test, for use on cobas® 6800 and cobas® 8800 Systems, is a qualitative in vitro test for the direct detection of Human Immunodeficiency Virus Type 1 (HIV-1) Group M RNA, HIV-1 Group O RNA, Human Immunodeficiency Virus Type 2 (HIV-2) RNA, Hepatitis C Virus (HCV) RNA, and Hepatitis B Virus (HBV) DNA in human plasma and serum. The cobas® MPX test simultaneously detects and discriminates for HIV, HCV, and HBV. The assay does not discriminate between HIV-1 Group M, HIV-1 Group O, and HIV-2.This test is intended for use to screen donor samples for HIV-1 Group M RNA, HIV-1 Group O RNA, HIV-2 RNA, HCV RNA, and HBV DNA in plasma and serum samples from individual human donors, including donors of whole blood, blood components, source plasma and other living donors. This test is also intended for use to screen organ and tissue donors when donor samples are obtained while the donor's heart is still beating and in testing of cadaveric (non- heart beating) donors. For donations of whole blood and blood components, plasma and serum samples are tested individually. For donations from cadaveric (non-heart beating) organ and tissue donors, samples are tested individually. For donations of source plasma, samples may be tested in pools comprised of aliquots of no more than 96 individual samples when the source plasma is intended for further manufacture into plasma derived products that undergo pathogen inactivation and/or removal procedures. The individual source plasma is collected from donors of plasma fractionation which is further manufactured into plasma-derived products which include viral inactivation and removal procedures only. This test is intended to be used in conjunction with licensed serology tests for HIV, HCV, and HBV.For an individual sample, results are simultaneously detected and discriminated for HIV, HCV, and HBV.The cobas® MPX test can be considered a supplemental test that confirms HIV infection for samples that are repeatedly reactive on a licensed donor screening test for antibodies to HIV and reactive on the cobas® MPX test.The cobas® MPX test can be considered a supplemental test that confirms HCV infection for samples that are repeatedly reactive on a licensed donor screening test for antibodies to HCV and reactive on the cobas® MPX test.The cobas® MPX test can be considered a supplemental test that confirms HBV infection for samples that are repeatedly reactive on a licensed donor screening test for Hepatitis B surface antigen and reactive on the cobas® MPX test.This test is not intended for use as an aid in diagnosis of infection with HIV, HCV, or HBV. en cobas® MPX for use on the cobas® 6800, cobas® 8800 and cobas® 5800 Systems is an in vitro test for the direct qualitative detection of human immunodeficiency virus type 1 (HIV-1) group M RNA, HIV-1 group O RNA, human immunodeficiency virus type 2 (HIV-2) RNA, hepatitis C virus (HCV) RNA and hepatitis B virus (HBV) DNA in human plasma or serum. cobas® MPX simultaneously detects and discriminates between HIV, HCV and HBV infections but is unable to discriminate between HIV-1 group M, HIV-1 group O and HIV-2.This test is mainly used to screen for HIV-1 group M RNA, HCV RNA and HBV DNA in plasma and serum samples from blood donors, including donors of whole blood, blood components and plasma as well as donors of living organs and tissues. For whole blood and all blood components that are donated, plasma and serum samples can be tested individually, or in the case of plasma, samples can be tested in pools of up to 6. For donors of hematopoietic stem/progenitor cells (HPC) from bone marrow, peripheral or cord blood, and for donors of lymphocytes for infusion (DLI), plasma can be tested in pools of up to 6 samples. For donated source plasma, samples can be tested in pools of up to 96. For all other donors, samples can only be screened individually.This test can be used in conjunction with approved serological detection reagents for HIV-1, HCV and HBV.This test may not be used as an aid in the diagnosis of HIV, HCV or HBV.This test may not be used to test samples of cord blood.For samples that get repeatedly reactive results in a confirmed HIV antibody test and HIV-reactive results in a cobas® MPX test, the cobas® MPX test can serve as a supplemental test to confirm HIV infection.For samples that get repeatedly reactive results in a certified HCV antibody test and HCV-reactive results in a cobas® MPX test, the cobas® MPX test can serve as a supplemental test to confirm HCV infection.For samples that get repeatedly reactive results in a certified HBV surface antigen test and HBV-reactive results in a cobas® MPX test, the cobas® MPX test can serve as a supplemental test to confirm HBV infection. en cobas® MPX is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consists of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report, or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR IVD (cobas® Synergy Core), may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four kit controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).33-35 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® MPX master mix contains detection probes which are specific for HIV-1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC.36,37 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific singlestranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible.33. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-128.34. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995; 373:487-493.35. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.37. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en The cobas® MPX test is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consists of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report, or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR IVD (cobas® Synergy Core), may optionally be used in a pre-analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four external controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon).32-34 Any contaminating amplicons from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicons are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® MPX master mix contains detection probes which are specific for HIV-1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC.35,36 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible.32. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-128.33. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995; 373:487-493.34. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.35. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.36. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en cobas® MPX is based on real time PCR technology on a fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection system. The cobas® 6800/8800 Systems consist of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report , or sent to a Laboratory Information Management System (LIMS) or other result management system.Samples can either be tested individually or, optionally, can be tested in pools consisting of multiple samples. The cobas p 680 instrument may optionally be used in a pre -analytical step if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four external controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured prot ein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 33-35 Any contaminating amplicon from previous PCR runs are eliminated by the AmpErase enzyme [uracil- N-glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicon are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® MPX master mix contains detection probes which are specific for HIV -1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of fou r unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC. 36, 37 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single-stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible.33. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-128.34. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995; 373:487-493.35. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.37. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en The cobas® MPX test is based on fully automated sample preparation (nucleic acid extraction and purification) followed by PCR amplification and detection. The cobas® 6800/8800 Systems consists of the sample supply module, the transfer module, the processing module, and the analytic module. Automated data management is performed by the cobas® 6800/8800 software which assigns test results for all tests as non-reactive, reactive, or invalid. Results can be reviewed directly on the system screen, and printed as a report or sent to a Laboratory Information Management System (LIMS) or other result management system.Source plasma (collected by Apheresis) samples may either be tested individually or, optionally, in pools consisting of up to 96 samples. The cobas p 680 instrument, or cobas® Synergy software with the Hamilton MICROLAB® STAR IVD system (together referred to as cobas® Synergy Core), must be used if pooling is to be performed.Nucleic acid from the sample and added armored RNA internal control (IC) molecules (which serve as the sample preparation and amplification/detection process control) is simultaneously extracted. In addition the test utilizes four external controls: three positive and a negative control. Viral nucleic acid is released by addition of proteinase and lysis reagent to the sample. The released nucleic acid binds to the silica surface of the added magnetic glass particles. Unbound substances and impurities, such as denatured protein, cellular debris, and potential PCR inhibitors (such as hemoglobin) are removed with subsequent wash reagent steps and purified nucleic acid is eluted from the magnetic glass particles with elution buffer at elevated temperature.Selective amplification of target nucleic acid from the donor sample is achieved by the use of virus-specific forward and reverse primers which are selected from highly conserved regions of the viral nucleic acid. A thermostable DNA polymerase enzyme is used for both reverse-transcription and amplification. The master mix includes deoxyuridine triphosphate (dUTP), instead of deoxythimidine triphosphate (dTTP), which is incorporated into the newly synthesized DNA (amplicon). 32-34 Any contaminating amplicons from previous PCR runs are eliminated by the AmpErase enzyme [uracil-N- glycosylase], which is included in the PCR master mix, when heated in the first thermal cycling step. However, newly formed amplicons are not eliminated since the AmpErase enzyme is inactivated once exposed to temperatures above 55°C.The cobas® MPX master mix contains detection probes which are specific for HIV-1 (Groups M and O), HIV-2, HCV, HBV, and IC nucleic acid. The specific HIV, HCV, HBV, and IC detection probes are each labeled with one of four unique fluorescent dyes which act as a reporter. Each probe also has a fifth dye which acts as a quencher. The four reporter dyes are measured at defined wavelengths, thus permitting simultaneous detection and discrimination of the amplified HIV, HCV, and HBV targets and the IC. 35,36 When not bound to the target sequence, the fluorescent signal of the intact probes is suppressed by the quencher dye. During the PCR amplification step, hybridization of the probes to the specific single- stranded DNA template results in cleavage by the 5' to 3' nuclease activity of the DNA polymerase resulting in separation of the reporter and quencher dyes and the generation of a fluorescent signal. With each PCR cycle, increasing amounts of cleaved probes are generated and the cumulative signal of the reporter dye is concomitantly increased. Since the four specific reporter dyes are measured at defined wavelengths, simultaneous detection and discrimination of the amplified HIV, HCV and HBV targets and the IC are possible.32. Longo MC, Berninger MS, Hartley JL. Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions. Gene. 1990; 93:125-128.33. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase. Nature. 1995; 373:487-493.34. Mol CD, Arvai AS, Slupphaug G, et al. Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995;80:869-878.35. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.36. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR. Genome Res. 1996;6:986-994. en cobas® MPX is based on real-time fluorescence PCR technology and is used on a system that fully automates sample preparation (nucleic acid extraction and purification) and PCR amplification and detection. The cobas® 5800 System consists of a single integrated instrument. The cobas® 6800/8800 Systems consist of a sample supply module, a transfer module, a processing module and an analysis module. The data is managed automatically by the cobas® 5800 or the 6800/8800 System software. For each test, the software determines whether the result is non-reactive, reactive or invalid. When using the cobas® 5800 System, the cobas® Synergy software is recommended for reviewing results and printing reports, and it is required to send results to a Laboratory Information Management System (LIMS) or other result management system. When using the cobas® 6800/8800 Systems, results can be reviewed directly on the system screen, printed as a report, or sent to a LIMS or other result management system.Samples can be tested individually or tested in pools containing multiple samples. If pooled testing is done, the cobas® Synergy software along with the Hamilton MICROLAB® STAR/STARlet IVD can be used for pooling before the analysis.The nucleic acid in the sample and the added armored RNA internal control (IC) (serving as the control for the sample preparation and amplification/detection processes) are extracted simultaneously. In addition, the test uses 4 kit controls: 3 positive controls and 1 negative control. Proteinase and lysis reagent are added to the sample to release the viral nucleic acid, and the released nucleic acid binds to the silica surface of the magnetic glass beads. Unbound substances and impurities, such as denatured protein, cellular debris and potential PCR inhibitors (such as hemoglobin) are removed in the subsequent washing steps, and purified nucleotides are eluted from the magnetic glass beads in the elution buffer using high temperature.The target nucleic acid in the sample is selectively amplified with virus-specific forward and reverse primers based on highly conserved regions of the viral nucleic acid. For HIV-1 group M, two different regions of the viral genome are amplified (dual targeting). A thermostable DNA polymerase is used for both the reverse transcription and the amplification. The master mix contains deoxyuridine triphosphate (dUTP) and AmpErase enzyme [uracil-N-glycosylase], and the dUTP instead of deoxythymidine triphosphate (dTTP) is incorporated into the newly synthesized DNA (the amplicon)33–35. In the first thermal cycling step, the AmpErase enzyme identifies the dUTP in the amplicons from previous PCR amplification reactions, thereby eliminating all amplicon contamination. After that, the temperature is raised above 55°C, and AmpErase is inactivated. Therefore newly formed amplicons are not eliminated.The cobas® MPX master mix contains detection probes that can bind specifically with the nucleic acids of HIV-1 (groups M and O), HIV-2, HCV, HBV and the IC. Detection probes for each HIV-1 Group M target are included, along with dual probes for HCV. The HIV-, HCV-, HBV- and IC-specific detection probes are each labeled with a unique fluorescent dye that acts as a reporter. Each probe is also labeled with a dye that acts as a quencher. These 4 reporter dyes are detectable at defined wavelengths. This allows for the simultaneous detection of and discrimination between the amplified HIV, HCV and HBV target sequences and the internal target (IC)36, 37. As for intact probes not bound to the target sequences, their fluorescent signals are suppressed by the quencher dye. During the PCR amplification step, these probes hybridize to the specific single-stranded DNA template, causing the DNA polymerase to cleave it through its 5' to 3' nuclease activity. This causes the reporter dye and the quencher dye to separate and generate a fluorescent signal. In each PCR cycle, as the number of cleaved probes continues to increase, the cumulative reporter dye signal also increases. The fact that the 4 specific reporter dyes are detected at defined wavelengths makes it possible to simultaneously detect and discriminate between the amplified HIV, HCV and HBV target sequences and the internal target (IC).33. Longo MC, Berninger MS, Hartley JL.Use of uracil DNA glycosylase to control carry-over contamination in polymerase chain reactions.Gene.1990; 93:125-128.34. Savva R, McAuley-Hecht K, Brown T, Pearl L. The structural basis of specific base-excision repair by uracil-DNA glycosylase.Nature.1995; 373:487-493.35. Mol CD, Arvai AS, Slupphaug G, et al.Crystal structure and mutational analysis of human uracil-DNA glycosylase: structural basis for specificity and catalysis. Cell. 1995; 80:869-878.36. Higuchi R, Dollinger G, Walsh PS, Griffith R. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (NY). 1992;10:413-417.37. Heid CA, Stevens J, Livak JK, Williams PM. Real time quantitative PCR.Genome Res.1996;6:986-994. en

cobas^® MPX

Ngăn chặn sự lây nhiễm của HIV, HCV, HBV qua đường truyền máu

IVD

Một xét nghiệm, ba kết quả

Phát hiện và phân biệt các vi rút mục tiêu trong một xét nghiệm dễ dàng sử dụng

Xét nghiệm cobas^® MPX là một xét nghiệm Real-time PCR đa mồi, nhuộm đa màu để phát hiện vi rút HIV, HCV và HBV được sử dụng trên hệ thống cobas^® 5800/6800/8800.

Đặc điểm và lợi ích

Phát hiện và phân biệt vi rút đích HIV, HCV, HBV
Phát hiện 5 vi rút mục tiêu quan trọng trong một xét nghiệm duy nhất (HIV-1 nhóm M, HIV-1 nhóm O, HIV-2, HCV và HBV)
Phương pháp tiếp cận mục tiêu kép với việc khuếch đại các vùng riêng biệt của HIV-1
Đầu dò kép cho HCV để cải thiện độ bao phủ các biến thể vi rút mới
Độ nhạy cao với HBV, phát hiện nhiễm HBV tiềm ẩn và tải lượng vi rút thấp

Đồng nhất quy trình làm việc và đảm bảo kết quả đáng tin cậy với xét nghiệm đa mồi tự động

Loại bỏ nhu cầu xét nghiệm bổ sung, loại bỏ các kết quả sai lệch tiềm ẩn
Thuốc thử sẵn sàng sử dụng - không cần rã đông, không cần khuấy hoặc trộn
Thuốc thử Real-time PCR ổn định, không cần hiệu chuẩn
Chứng nội kiểm soát toàn bộ quy trình giúp đảm bảo độ tin cậy của kết quả
Các biện pháp kiểm soát dương tính bên ngoài không ảnh hưởng đến việc tính toán kết quả với bộ mẫu chứng cobas^® MPX
Có thể chạy đồng thời với các xét nghiệm khác trên hệ thống cobas^® 5800/6800/8800

Công nghệ chẩn đoán tiên tiến cho giải pháp sàng lọc máu

Xét nghiệm cobas^® MPX cho phép phòng xét nghiệm sàng lọc máu kiểm tra 3 loại vi rút đích và 5 vi rút mục tiêu quan trọng một cách đáng tin cậy chỉ bằng một xét nghiệm duy nhất, nâng cao hiệu quả hoạt động bằng cách loại bỏ nhu cầu xét nghiệm bổ sung để phân biệt vi rút đích phản ứng.

Thông tin sản phẩm

Mục đích sử dụng

Xét nghiệm cobas^® MPX, sử dụng trên hệ thống cobas^® 5800/6800/8800 là xét nghiệm định tính in vitro dùng để phát hiện trực tiếp RNA vi rút gây suy giảm miễn dịch ở người tuýp 1 (HIV-1) nhóm M, RNA HIV-1 nhóm O, RNA vi rút gây suy giảm miễn dịch ở người tuýp 2 (HIV-2), RNA vi rút viêm gan C (HCV), và DNA vi rút viêm gan B trong huyết tương và huyết thanh người.

Xét nghiệm dùng để sàng lọc mẫu hiến tặng với RNA HIV-1 nhóm M, RNA HIV-1 nhóm O, RNA HIV-2, RNA HCV và DNA HBV trong mẫu huyết tương và huyết thanh từ người hiến riêng lẻ, bao gồm người hiến máu toàn phần, hiến các thành phần máu, và người hiến đang sống khác. Xét nghiệm cũng được sử dụng để sàng lọc tạng và mô hiến với mẫu được lấy từ người hiến khi tim vẫn còn đập và mẫu từ người hiến khi tim đã ngừng đập. Huyết tương và huyết thanh từ tất cả người hiến có thể được sàng lọc dưới dạng mẫu đơn. Đối với mẫu máu hiến toàn phần và các thành phần máu, các mẫu huyết tương và huyết thanh có thể được xét nghiệm dưới dạng mẫu đơn hoặc huyết tương có thể được xét nghiệm theo mẫu gộp bao gồm các phần mẫu từ các mẫu đơn. Đối với tạng và mô được lấy từ người hiến xác (tim không còn đập), các mẫu chỉ có thể được sàng lọc dưới dạng mẫu đơn.

Đối với mẫu đơn, kết quả được phát hiện đồng thời và phân biệt đối với HIV, HCV và HBV.

Xét nghiệm cobas^® MPX có thể được xem là một xét nghiệm bổ sung để khẳng định nhiễm HIV đối với các mẫu phản ứng lặp lại với một xét nghiệm CE-IVD cho kháng thể kháng HIV và phản ứng với xét nghiệm cobas^® MPX.

Xét nghiệm cobas^® MPX có thể được xem là một xét nghiệm bổ sung để khẳng định nhiễm HCV đối với các mẫu phản ứng lặp lại với một xét nghiệm CE-IVD cho kháng thể kháng HCV và phản ứng với xét nghiệm cobas^®MPX.

Xét nghiệm cobas^® MPX có thể được xem là một xét nghiệm bổ sung để khẳng định nhiễm HBV đối với các mẫu phản ứng lặp lại với một xét nghiệm CE-IVD cho kháng nguyên bề mặt của vi rút viêm gan B và phản ứng với xét nghiệm cobas^® MPX.

Xét nghiệm này cũng có thể được sử dụng để hỗ trợ chẩn đoán nhiễm HIV, HCV hay HBV trên các mẫu được thu thập từ những người bị nghi ngờ nhiễm các loại vi rút này bởi nhân viên y tế hoặc để sàng lọc những người chưa rõ tình trạng nhiễm HIV, HCV hoặc HBV.

Thông tin chung

Thông tin đặt hàng

Hệ thống xét nghiệm tương thích

Sản phẩm liên quan

Liên hệ

Nếu bạn có câu hỏi về các sản phẩm hoặc dịch vụ của chúng tôi, vui lòng điền vào biểu mẫu.
Đại diện kinh doanh của Roche sẽ liên hệ với bạn.

Thông tin đăng ký sản phẩm:

Thuốc thử xét nghiệm phát hiện RNA HIV-1 Nhóm M, RNA HIV-1 Nhóm O, RNA HIV-2, RNA HCV, DNA HBV
cobas® MPX

Chủ sở hữu số lưu hành:
Công ty TNHH Roche Việt Nam
Tầng 27, Tòa nhà Pearl Plaza, 561A Điện Biên Phủ, Phường Thạnh Mỹ Tây, Tp. Hồ Chí Minh, Việt Nam
Mã số tài liệu: MC-VN-01562

User profile

Select your user profile

cobas^® MPX

Một xét nghiệm, ba kết quả

Phát hiện và phân biệt các vi rút mục tiêu trong một xét nghiệm dễ dàng sử dụng

Đặc điểm và lợi ích

Đồng nhất quy trình làm việc và đảm bảo kết quả đáng tin cậy với xét nghiệm đa mồi tự động

Công nghệ chẩn đoán tiên tiến cho giải pháp sàng lọc máu

Thông tin sản phẩm

Thông tin chung

Thông tin đặt hàng

Tài liệu kỹ thuật

Truy cập các tài liệu sẵn có tại quốc gia của bạn

Hệ thống xét nghiệm tương thích

Sản phẩm liên quan

Liên hệ

User profile

Select your user profile

cobas® MPX

Một xét nghiệm, ba kết quả

Phát hiện và phân biệt các vi rút mục tiêu trong một xét nghiệm dễ dàng sử dụng

Đặc điểm và lợi ích

Đồng nhất quy trình làm việc và đảm bảo kết quả đáng tin cậy với xét nghiệm đa mồi tự động

Công nghệ chẩn đoán tiên tiến cho giải pháp sàng lọc máu

Thông tin liên quan

Thông tin sản phẩm

Thông tin chung

Thông tin đặt hàng

Tài liệu kỹ thuật

Truy cập các tài liệu sẵn có tại quốc gia của bạn

Hệ thống xét nghiệm tương thích

Sản phẩm liên quan

Liên hệ

cobas^® MPX